

素のβ-γ-セクレターゼを阻害し、海馬でのアミロイドβ蛋白の沈着を防ぐことが報告されている。今後詳細な検討は必要であるが、DHAはアルツハイマー病の治療剤である可能性が見出された。

DHAと同様に、魚油の主成分の一つであるEPAは既に血漿脂質改善薬として広く用いられている。以前から、脳内EPA量はEPA投与により影響を受けないことが報告されていることから、DHAと同じn-3系多価不飽和脂肪酸でありながら、EPAの中核作用は否定されていた。しかし、我々は、EPA投与ラットの海馬EPA量は増加し、さらにDHAも増加することを見出している。海馬で増加したDHAは認知機能を改善することが示唆されるが、事実、EPA投与ラットでは放射状迷路法による空間認知機能が亢進した(2004、日本脂質栄養学会発表)。本実験では、食餌性EPAにより、血漿と海馬のEPA量が増加し、ADモデルラットでの空間認知機能障害が軽減されることが見出された。このEPAによる予防効果はEPA単独の効果なのか、あるいはEPAから変換したDHAによる効果なのかは定かではないが、おそらく後者にもとづくものと推察している。

今回、ラット胎児脳から神経幹細胞を単離・培養する方法を確立した。さらに、DHAやEPA処理により神経細胞の軸索伸長作用がみられたが、特許申請の関係上、その詳細は次年度に報告する。

E. 結論

魚油の主成分であるDHAとEPAの摂取は、海馬での抗酸化作用を増強することによりアルツハイマー病を予防し、さらには改善効果をもたらすことが明らかにされた。

F. 研究発表

著書

1. 橋本道男 その他多数; 油化学事典—脂質・界面活性剤— 日本油化学会編、丸善、2004

論文

1. Ishtiaq Mahmud, Anwar Hossain, Shahdat Hossain, Abdul Hannan, Liaquat Ali, Michio Hashimoto. Effects of *Hilsa Ilsa* Fish oil on atherogenic lipid profile and glycaemic status of streptozotocin-treated type 1 diabetic rats. *Clinical and Experimental Pharmacology and Physiology* 2004; 31: 76-81
2. Kuninori Shiwaku, Michio Hashimoto, Akiko Nogi, Keiko Kitajima, Masayuki Yamasaki. Traditional Japanese dietary basics: a solution for modern health issues? *Lancet* 2004; 363 (9422): 1737-1738
3. Naoko Tanaka, Kumiko Kawasaki, Namie Neijme, Yoko Kubota, Kazuki Nakamura, Masaru Kunitomo, Koichi Takahashi, Michio Hashimoto, Kazumasa Shinozuka. P2Y receptor-mediated Ca²⁺ signaling increases human vascular endothelial cell permeability. *Journal of Pharmacological Sciences* 2004; 95: 174-180
4. Hossain Shahdat, Michio Hashimoto, Toshio Shimada, Osamu Shido. Synaptic plasma membrane-bound acetylcholinesterase activity is not affected by docosahexaenoic acid-induced decrease in membrane order. *Life Sciences* 2004; 74: 3009-3024
5. Kuninori Shiwaku, Michio Hashimoto, Keiko Kitajima, Akiko Nogi, Erdembileg Anuurad, Byambaa Enkhmaa, Jung-Man Kim, In-Shik Kim, Sung-Kook Lee, Tsendsuren Oyunsuren, Osamu Shido, Yosuke Yamane. Triglyceride levels are ethnic-specifically associated with an index of stearoyl-CoA desaturase activity and n-3 PUFA levels in Asians. *Journal of Lipid Research* 2004; 45: 914-922
6. Yoko Tanabe, Michio Hashimoto, Kozo Sugioka,

- Megumi Maruyama, Yoshimi Fujii, Rika Hasegawa, Toshiko Hara, Shahdat Md Hossain and Osamu Shido. Improvement of spatial cognition with dietary docosahexaenoic acid is associated with an increase in fos expression in rat CA1 hippocampus. *Clinical and Experimental Pharmacology and Physiology* 2004; 31: 700-703
7. Michio Hashimoto, Yoko Kubota, Noriko Tanaka, Yu Yamaguchi, Yoshimi Fujii, Satomi Kagota, Eisuke Kawakita, Osamu Shido, Masaru Kunitomo, Kazumasa Shinozuka. Relationship between plasma and hippocampal lipid peroxidation in obese and hypertensive SHR/NDmcr-cp rat. *Clinical and Experimental Pharmacology and Physiology* 2004; 31: S62-S64
 8. Naoko Tanaka, Namie Neijme, Satomi Kagota, Yoko Kubota, Kazuki Nakamura, Masaru Kunitomo, Michio Hashimoto, Ryuichi Yamamoto and Kazumasa Shinozuka. Dysfunction of purinergic regulation of sympathetic neurotransmission in SHR/NDmcr-cp (SHR-CP) rat. *Clinical and Experimental Pharmacology and Physiology* 2004; 31: S60-S61
 9. Michio Hashimoto, Yoko Tanabe, Yoshimi Fujii, Toshihiko Kikuta, Hitoshi Shibata, Osamu Shido. Chronic administration of docosahexaenoic acid ameliorates impairment of spatial cognition learning ability in amyloid β -infused rats. *Journal of Nutrition* 2005; in press
- SHR/NDmcr-cp (SHR-CP) rat. Lifestyle Related Diseases -Perspectives for Primary Prevention and Treatment in Animal Models and Humans- (Satellite Symposium to the 11th International Symposium on the SHR and Cardiovascular Risk -Genomics to Disease Prevention-); May 13, 2004, Spokane, WA, USA
2. Michio Hashimoto, Yoko Kubota, Naoko Tanaka, Yuko Yamaguchi, Yoshimi Fujii, Satomi Kagota, Osamu Shido, Masaru Kunitomo, Kazumasa Shinozuka. Age-related changes in fatty acid composition of plasma and hippocampus of Wistar-Kyoto and SHR/NDmcr-cp (SHR-cp) rats. Lifestyle Related Diseases -Perspectives for Primary Prevention and Treatment in Animal Models and Humans- (Satellite Symposium to the 11th International Symposium on the SHR and Cardiovascular Risk -Genomics to Disease Prevention-); May 13, 2004, Spokane, WA, USA
 3. Naoko Tanaka, Namie Neijme, Satomi Kagota, Yoko Kubota, Kazuya Nakamura, Masaru Kunitomo, Michio Hashimoto, Ryuichi Yamamoto, Kazumasa Shinozuka. Change of purinergic prejunctional modulation on NE-release from sympathetic nerves in the caudal artery of SHR/NDmcr-cp RAT (SHR-CP). The 11th International Symposium on the SHR and Cardiovascular Risk -Genomics to Disease Prevention; May 16-17, 2004, Portland, Ore., USA
 4. Michio Hashimoto, Yoko Kubota, Naoko Tanaka, Yuko Yamaguchi, Yoshimi Fujii, Satomi Kagota, Osamu Shido, Masaru Kunitomo, Kazumasa Shinozuka. Fatty acid composition and lipid peroxide of plasma and hippocampus of Wistar-Kyoto and SHR/NDmcr-cp (SHR-cp) rats.
- 国際学会発表
1. Naoko Tanaka, Namie Neijme, Satomi Kagota, Yoko Kubota, Kazuya Nakamura, Masaru Kunitomo, Michio Hashimoto, Ryuichi Yamamoto, Kazumasa Shinozuka. Dysfunction of purinergic regulation of sympathetic neurotransmission in

The 11th International Symposium on the SHR and Cardiovascular Risk –Genomics to Disease Prevention; May 16-17, 2004, Portland, Ore., USA

5. M Hashimoto, Y tanabe, Y Fujii, T Harada, A Kawashima, E Kawakita, T Yano, K Mizuguchi, A Ueki, O Shido. An improvement effect of spatial cognitive functions with dietary eicosahexaenoic acid in young rats. International Academy Nutrition and Aging (IANA) Symposium on nutrition and Alzheimer's Disease, October 1-2, 2004, Tokyo, Japan
6. M Hashimoto, Y tanabe, Y Fujii, E Kawakita, T kikuta, H Shibata, O Shido. Post-administration with docosahexaenoic acid has an improved effect on the impairment of spatial cognition learning ability in Alzheimer's disease model rats. International Academy Nutrition and Aging (IANA) Symposium on nutrition and Alzheimer's Disease, October 1-2, 2004, Tokyo, Japan
7. M.A Haque, Michio Hashimoto, Yoko tanabe, Yukihiko Hara, Osamu Shido. Chronic administration of polyphenon E improves spatial cognitive learning ability in rats. 2004 International Conference on O-cha (tea) culture and Science, November 4-6, 2004, Shizuoka, Japan

国内発表

1. 橋本道男、田邊洋子、矢野 崇、藤井由己、原田剛、川島晶子、川北映輔、水口 清、紫藤 治: エイコサペンタエン酸によるラット記憶・学習機能向上効果 第13回日本脂質栄養学会、山形、9月3-4日、2004

G. 知的財産権の出願・登録状況(予定を含む)

1. 特許取得

- 1) 平成16年9月2日、茶カテキン類を有効成分とする空間認知機能改善剤、発明者:原 征彦・橋本道男・紫藤 治、出願人:原 征彦・橋本道男、日本国、特願2004-255373
- 2) 平成16年11月9日、認知機能障害治療剤、発明者:飛永精照・恒松徳五郎・橋本道男・田口恭治・宇都宮 郁、出願者:飛永精照、日本国、特願2004-325222

2. 実用新案登録

なし

Z00400337 A

厚生労働科学研究研究費補助金

痴呆・骨折臨床研究事業

痴呆の予防・治療と食事栄養

(H16-痴呆・骨折-002)

平成16年度 総括・分担研究報告書

2/2冊

主任研究者 植木 彰

平成17(2005)年 4月

研究成果の刊行に関する一覧表

雑誌

発表者氏名	論文タイトル名	発表雑誌名	巻号	ページ	出版年
Akira Ueki, Mieko Otsuka	Life style risks of Parkinson's disease: Association between decreased water intake and constipation	J Neurol	251(7)	18-23	2004
Nobuto Shibata, Tohru Ohnuma, Tadashi Takahashi, Yoichiro Matsubara, Akira Ueki, Masatsugu Nagao, Heii Arai	No genetic association between tumour necrosis factor receptor II 196R polymorphism and Japanese sporadic Alzheimer's disease	Lippincott Williams & Wilkins		53-55	2004
K. Yamashita, Y. Sakamura	Relationships between Depression and Dietary Variety in Elderly People Living in a Community	Asia Pacific Health of the Elderly in Rapidly Aging Societies			2004
宮永 和夫	抗痴呆薬の効果と今後の展開	痴呆介護	5(2)	56-64	2004
宮永 和夫	痴呆の治療	日本老年医学会	42(1)	49-51	2005
Sayoko Hattori, Kenji Sakuma, Yosuke Wakutani, Kenji Wada, Masaru Shimoda, Katsuya Urakami, Hisanori Kowa, Kenji Nakashima	A novel presenilin 1 mutation(Y154N) in a patient with early onset Alzheimer's disease with spastic paraparesis	Neuroscience Letters	368	319-322	2004
Yosuke Wakutani, Hisanori Kowa, Masayoshi Kusumi, Kazuhiro Nakaso, Ken-ichi Yasui, Kenji Isoe-Wada, Hidetaka Yano, Katsuya Urakami, Takao Takeshima, Kenji Nakashima	A haplotype of the methylenetetrahydrofolate reductase gene is protective late-onset Alzheimer's disease	Neurobiology of Aging	25	291-294	2004
M. Kusumi, H. Arai, T. Ijiri, H. Kowa, Y. Adachi, T. Takashima, F. Sakurai, K. Nakashima	Serotonin 2C receptoe gene Cys23Ser polymorphism: a candidate genetic risk factor of migraine with aura in Japanese population	Acta Neurol Scandinavica	109	407-409	2004
須貝 佑一、小林 奈美	施設における痴呆高齢者の転倒・転落事故の発生状況と対策	看護学雑誌	68/1	10-18	2004

須貝 佑一	脳変性疾患における痴呆の知識 第4回ピック病	痴呆介護	5(4)	84-87	2004
須貝 佑一、丸井 英二 松村 康弘、林 邦彦 杉下 知子	高齢者の生活習慣と知的機能	第19回日本老年精神医学会 プログラム・抄録集		67	2004
Yuichi Sugai	Association between cognitive function and life style of old ages	Proceedings of The 19th conference of the Japanese Psychogeriatric Society (in press)			2004
須貝 佑一	介護保険制度を通じた保健・医療・福祉の統合と課題	精神医学	46(10)	1035-1040	2004
Yumiko Motoi, Masako Itaya, Hideo Mori, Yoshikuni Mizuno, Tadao Iwasaki, Hiroaki Hattori, Seichi Haga, Kazuhiko Ikeda	Apolipoprotein E receptor 2 is involved in neuritic plaque formation in APP sw mice	Neuroscience Letters	368	144-147	2004
K Iwamoto, C Kikuchi, M Bundo, K Ikeda, T Kato	Molecular characterization of bipolar disorder by comparing gene expression profiles of postmortem brains of major mental disorder	Molecular Psychiatry		1-11	2004
Hossain Shahdat, Michio Hashimoto, Toshio Shimada, Osamu Shido	Synaptic plasma membrane-bound acetylcholinesterase activity is not affected by docosahexaenoic acid-induced decrease in membrane order	Life Sciences	74	3009-3024	2004
Michio Hashimoto, Yoko Tanabe, Yoshimi Fujii, Toshihiko Kikuta, Hitoshi Shibata	Chronic Administration of Docosahexaenoic Acid Ameliorates the Impairment of Spatial Cognition Learning Ability in Amyloid B-Infused Rats	J Nutr.	135(3)	549-555	2005
Yoko Tanabe, Michio Hashimoto, Kozu Sugioka, Megumi Maruyama, Yoshimi Fujii, Rika Hagiwara, Toshiko Hara, Shahdat Md Hossain and Osamu Shido	Improvement of spatial cognition with dietary docosahexaenoic acid is associated with an increase in fos expression in rat CA1 hippocampus	Clinical and Experimental Pharmacology and Physiology	31	700-703	2004

Akira Ueki
Mieko Otsuka

Life style risks of Parkinson's disease: Association between decreased water intake and constipation

Abstract Gastrointestinal dysfunction, especially constipation, is one of the major problems in the daily life of patients with Parkinson's disease (PD). About 60 to 80% of PD patients suffer from constipation. Several studies have proven that constipation appears about 10 to 20 years prior to motor symptoms. More recently, Abbott et al. have found from a large scale prospective study that lower frequency bowel movements predict the future risk of PD. Furthermore, Braak et al. have found that Lewy neuritis and Lewy bodies, the hallmarks of PD pathology, appear in the dorsal nucleus of vagus in the earliest stage of the disease and then extend upward through the brain stem to reach the substantia nigra in the third stage. They also hypothesize that some yet undefined toxins break through the mucosal barrier of the intestine and are incorporated into the axon terminal of the vagus nerve and trans-

ported in a retrograde manner to the vagus nucleus. In this study, we assessed bowel movements and nutritional status in Japanese patients with PD. We found that intake of water was significantly decreased in PD patients from early life and associated with their constipation.

Ninety four patients with PD (M 50, F 44) were enrolled. Nutritional status was assessed using the Self-administered Diet History Questionnaire (DHQ). Total water intake was calculated from the consumption of coffee, green tea, and tea. We also questioned the behavior of water drinking from the early stage of life. The questionnaire for bowel movements concerned the frequency of defecation, age of onset of constipation, and age of onset of motor dysfunction. Less than one bowel movement in 3 days was defined as constipation.

The nutritional status of PD patients did not differ significantly from those of controls though several studies have shown excess intake of animal fats or reduced consumption of coffee are risks in PD. In contrast, water intake was significantly lower in PD patients than controls (604.0 ± 377.2 ml/d vs 909.5 ± 531.6 ml/d; $P < 0.0001$). Interestingly, PD patients tended not to feel thirsty and thus they had no desire to drink water throughout

their life. Seventy four patients out of 94 (78.7%) complained of constipation. Mean bowel frequency was once per 3.3 ± 1.1 days and 71.1% of patients were defined as having constipation. Women suffered from constipation more frequently than men (82.4% vs 61.9%). In 33 patients out of 74 (44.6%), onset of constipation preceded motor disturbance by an average time of 18.1 ± 18.8 years. Furthermore, the amount of water intake correlated inversely with the severity of constipation and the depletion of water intake preceded constipation in most cases.

The present results support previous findings that constipation precedes the onset of motor dysfunction in PD. To our knowledge, this is the first report to point out latent water depletion in PD patients. It is not certain at present whether coffee or caffeine themselves are the protective factor for PD or alternatively the amount of water in coffee drinking is more essential. Prospective studies on a large scale are necessary to elucidate the real meaning of water depletion in PD.

Key words Parkinson's disease · constipation · water deficiency · nutritional factor · early diagnostic marker

Akira Ueki, MD (✉) · Mieko Otsuka
Department of Neurology
Jichi Medical School
Omiya Medical Center
1-847 Amanuma-cho, Omiya-ku
Saitama-City
Saitama 330-8503, Japan
Tel.: 048-647-2111
Fax: 048-648-5188
E-Mail: uekia@omiya.jichi.ac.jp

Introduction

Research on the cause of Parkinson's disease (PD) points to both genetic and acquired factors. Over 10 genes causing familial PD have already been identified, but no genetic polymorphism has been confirmed for a majority of sporadic Parkinson's disease patients. Acquired factors are divided into environmental and lifestyle factors. Since the discovery of MPTP, there has been increased interest in environmental toxins, and the relationship between PD and exposure to insecticides with chemical structures similar to MPTP is being investigated, although there have as yet been no reports confirming a connection. Lifestyle factors include nutrition, exercise and rest, as well as alcohol consumption and smoking. Recently, there have also been reports of numerous prospective studies indicating that the lower the degree of coffee consumption, the higher the risk of developing PD [1, 2], drawing attention to the defensive effect of caffeine.

It has also been pointed out that there is a high incidence rate of constipation associated with PD, and that constipation appears 10 or more years prior to motor symptoms. Furthermore, it was recently reported that a large-scale prospective study conducted in Hawaii clearly showed that the lower the stool frequency at the beginning of the study, the higher the risk of developing PD in the future, confirming that constipation clearly precedes motor dysfunction in PD [3]. A series of pathological trials conducted by Braak et al. [4, 5] showed that Lewy neurites and Lewy bodies, the hallmarks of PD pathology, appear in the dorsal nucleus of vagus in the earliest stage of the disease. The lesions then extend upwards through the brain stem to eventually cause disturbance in the substantia nigra and the vagus nerve, resulting in reduced gastrointestinal movement, which is thought to explain the clinical findings that precede motor symptoms. Braak et al. also proposed the attractive hypothesis that an unidentified toxin passes through the mucosal barrier of the intestine and is transported in a retrograde manner by the vagus nerve axon, leading to vagus nerve neuron damage [6].

In light of this information, we conducted a study of constipation and nutritional status in PD patients, and sampled characteristic nutritional factors in PD while investigating whether constipation is related to nutrients, and whether there is a temporal relationship between constipation and nutrients and the appearance of motor symptoms. The results indicated that, in PD, constipation precedes the onset of motor dysfunction by roughly 20 years, and is accompanied by the dietary factor of insufficient uptake of water, pointing to a close relationship between constipation and insufficient water uptake.

Subjects

The subjects were 94 PD patients (M 50, F 44), in whom the onset age was 59.5 ± 10.4 years (M 58.4 ± 10.4 , F 60.7 ± 10.3), and age at the time of the study was 68.1 ± 8.6 years (M 67.4 ± 9.6 , F 69.1 ± 7.5). The control group consisted of 69 healthy adults of corresponding age not suffering from diabetes, hypertension, hyperlipidemia, or nervous disease.

Methods

Food and nutrient intake per energy intake of 1,000 kcal was calculated using the Self-administered Diet History Questionnaire (DHQ) from Dietary assessment: Sasaki et al. [7]. Strictly speaking, total water intake is calculated to include intake of green tea, coffee, tea, juice, hot water and other drinks, as well as metabolic water, but in this study, because the amount of metabolic water was less than 10% of the drinking water, only the amount of drinking water was calculated. In a survey of water intake, subjects were asked how much desire they had to drink water, including green tea, tea, coffee and other drinks, with answers classified as "Very little", "Little", "Normal", and "Much". They were also asked to state, as accurately as possible, when this drinking pattern first developed.

☒ Constipation survey items

Subjects were asked how frequent their bowel movements were, and constipation was defined as less than one bowel movement in 3 days. They were also asked about the sequential relationship between when symptoms of constipation first appeared, when motor symptoms first appeared, and when their water intake behavior changed.

☒ Statistical analysis

Data were analyzed using one-way analysis of variance (ANOVA) to determine the significance of differences among groups.

Results

☒ Nutritional assessment

Apart from a significantly low intake of fish, alcohol and water, the nutritional status of the PD patients did not differ from that of the controls with respect to the 18 specified food groups (Table 1). The most striking difference was water intake, with the controls drinking 597.1 ± 402.5 ml per 1,000 kcal per day compared to the significantly lower amount of 341.3 ± 209.0 ml for the PD patients ($P < 0.0001$). Even when comparing the absolute volume of water intake, the 604.0 ± 377.2 ml of the PD patients was significantly lower than the 909.5 ± 531 ml of the controls ($P < 0.0001$).

In terms of nutrients, the PD patients and controls showed little significant difference in intake of vitamin B₂, niacin, vitamin C and ethanol (Table 2). In terms of lipids, reflecting little intake of fish, the polyunsaturated fatty acid (PUFA) n-6/n-3 ratio was high (Table 3).

Table 1 Food groups (unit = g)

	PD (n = 80)	Control (n = 69)	P value
Grains	264.8 ± 77.0	235.2 ± 97.6	NS
Potatoes	21.7 ± 18.1	20.9 ± 15.1	NS
Sugar	4.4 ± 2.7	5.9 ± 4.6	NS
Snacks	14.5 ± 11.7	15.3 ± 12.5	NS
Beans	144.6 ± 85.6	123.8 ± 70.7	NS
Fish	44.3 ± 22.5	55.8 ± 29.5	0.008
Meat	22.5 ± 14.5	19.7 ± 15.2	NS
Eggs	13.3 ± 9.5	12.8 ± 11.4	NS
Milk	105.5 ± 87.8	117.1 ± 103.2	NS
Green vegetables	58.1 ± 33.9	71.0 ± 65.6	NS
Other vegetables	69.8 ± 34.6	70.2 ± 53.4	NS
Fruit	87.2 ± 50.8	85.3 ± 50.4	NS
Mushrooms	7.3 ± 6.5	6.6 ± 7.1	NS
Seaweeds	8.9 ± 9.1	10.4 ± 8.9	NS
Beverages	41.7 ± 95.4	91.0 ± 188.0	0.041
Water (tea, coffee, juice)	341.3 ± 209.0	597.1 ± 402.5	< 0.0001
Seasoning	41.3 ± 41.2	38.0 ± 45.8	NS

Table 2 Nutrients/1,000 kcal

		PD (n = 80)	Control (n = 69)	P value
T.protein	%E	15.0 ± 2.5	15.6 ± 3.5	NS
T.fat	%E	24.4 ± 6.0	24.2 ± 7.9	NS
T.carbohydrate	%E	57.7 ± 7.7	55.2 ± 9.7	NS
Na	mg	2893.2 ± 735.2	2824.9 ± 868.5	NS
K	mg	1386.3 ± 378.8	1522.2 ± 484.7	NS
Ca	mg	358.2 ± 130.4	397.2 ± 160.1	NS
P	mg	589.6 ± 131.7	623.7 ± 165.6	NS
Fe	mg	5.2 ± 1.2	5.4 ± 1.6	NS
Vit.A	IU	1403.3 ± 791.4	1474.7 ± 1008.4	NS
Vit.B ₁	mg	0.5 ± 0.1	0.5 ± 0.1	NS
Vit.B ₂	mg	0.8 ± 0.2	0.9 ± 0.3	0.003
Niacin	mg	7.6 ± 2.1	8.4 ± 2.4	0.043
Vit.C	mg	74.3 ± 36.8	87.1 ± 40.2	0.043
Carotene	µg	1384.2 ± 942.6	1523.2 ± 1172.1	NS
Alcohol	%E	2.0 ± 4.2	3.9 ± 7.1	0.048

Table 3 Nutrients2

		PD (n = 80)	Control (n = 69)	P value
Lipids				
Cholesterol	mg	141.2 ± 53.6	148.1 ± 70.5	NS
SFA	%E	7.1 ± 2.3	7.1 ± 3.0	NS
MUFA	%E	8.2 ± 2.4	8.0 ± 2.8	NS
PUFA	%E	6.3 ± 1.7	6.3 ± 2.1	NS
n-3 PUFA	%E	1.3 ± 0.5	1.5 ± 0.6	NS
n-6 PUFA	%E	5.1 ± 1.3	4.9 ± 1.5	NS
n-6/n-3 PUFA		4.0 ± 0.9	3.5 ± 1.0	0.002
Fibers				
water soluble	g	8.5 ± 2.7	8.3 ± 2.8	NS
insoluble	g	1.5 ± 0.5	1.4 ± 0.5	NS
	g	6.5 ± 1.9	6.2 ± 2.0	NS

SFA saturated fatty acid; MUFA monounsaturated fatty acid; PUFA polyunsaturated fatty acid

Degree of desire to drink water

Table 4 shows the results of the water drinking behavior survey. Of the 94 subjects, 44 (46.8%) answered "Very little", and 20 (21.3%) answered "Little". The water intake for each of these two groups was less than 300 ml and between 300 and 600 ml respectively. Of the remaining subjects, 27 (28.7%) answered "Normal" (600 to 1,000 ml/day), and 3 (3.2%) answered "Much" (over 1,000 ml/day). A majority of PD patient families, including spouses, are aware that the patient drinks very little, and many believe the amount drunk is insufficient.

Frequency of bowel movements

Mean bowel movement frequency was once every 3.3 ± 1.1 days, with a frequency of once every 3.3 ± 1.1 days for men and once every 3.3 ± 1.1 days for women, constipation being more severe among women. These results were obtained from 38 patients. Constipation was defined as less than one bowel movement in 3 days. Overall, 71.1% of the patients were constipated, with 61.9% of men and 82.4% of women being constipated (Table 5).

Relation between constipation and motor symptoms

Table 6 shows the temporal relationship between constipation and the onset of motor symptoms. Among the 74

Table 4 Water drinking behavior in parkinsonian patients

Degree of desire to drink (ml/d)	Total n (%)	Men n (%)	Women n (%)
Very little (300)	56 (46.7)	24 (38.7)	32 (55.2)
Little (300-600)	31 (25.8)	16 (25.8)	15 (25.9)
Normal (600-1,000)	27 (22.5)	8 (29.0)	9 (15.5)
Much (> 1,000)	3 (2.5)	2 (3.2)	1 (1.7)
Unknown	3 (2.5)	2 (3.2)	1 (1.7)
Total	120 (100.0)	62 (100.0)	58 (100.0)

Table 5 Frequency of bowel movements

Interval for bowel defecation (days)	Total (n = 38)	Men (n = 21)	Women (n = 17)
1	5	2	3
2	6	6	0
3	12	5	7
4	7	4	3
5	4	3	1
6	2	1	1
> 3 days	27 (71.1%)	13 (61.9%)	14 (82.4%)

Table 6 Onset of constipation in relation to motor symptoms

Onset of Constipation	Total n (%)	Men n (%)	Women n (%)
Before PD	49 (50.5)	23 (43.4)	26 (59.1)
After PD	14 (14.4)	11 (20.8)	3 (6.8)
Unknown	34 (35.1)	19 (35.8)	15 (34.1)
Total	97 (100.0)	53 (100.0)	44 (100.0)

patients who responded, 33 (44.6%) suffered from constipation before the onset of motor symptoms, 14 (18.9%) became constipated following the onset of motor symptoms, and for 27 patients (36.5%) the relationship was unclear, indicating that the percentage of patients with constipation before the onset of motor symptoms was high.

Among patients who had constipation before onset of PD, the mean age at which constipation began was 39.9 ± 22.0 (45.8 ± 19.2 for men, 33.1 ± 23.6 for women). Constipation began a mean 18.7 ± 18.8 years before the appearance of motor symptoms, the figure being 12.6 ± 16.4 years earlier for men and 25.5 ± 19.9 years for women. Cases of patients who had constipation from childhood and university were also accurately recorded.

Relation between constipation and adipsia

Among the 74 patients suffering from constipation, when asked how much water they drank, 35 (47.3%) answered "None", 17 (23%) answered "Hardly any", 21 (28.4%) answered "Normal amount", and 1 (1.4%) answered "A large amount", indicating that 70.3% of the patients drank none or very little water. Among the 10 patients without constipation, 4 (40%) answered "None", 0 (0%) answered "Hardly any", 4 (40%) answered "Normal amount", and 2 (20%) answered "A large amount", but since the number of cases in this group was small, this did not indicate any significant statistical difference. A tendency for motor symptoms to be lighter in patients who drank large amounts of water was also observed, but no precise relationship between water intake and symptom severity could be ascertained in this study.

Sequence of adipsia, constipation and motor symptoms

Responses were received from 43 patients concerning the temporal relationship between insufficient water intake, constipation and motor symptoms (Table 7). In 31 (72.1%) cases, the majority, adipsia occurred first followed by constipation and then motor dysfunction, while there were only 3 (6.9%) cases in which constipation

Table 7 Sequence of adipsia, constipation, and motor symptoms

Adipsia → Constipation/Motor	31 (72.1%)
Constipation/Motor → Adipsia	3 (6.9%)
Undefined	9 (21%)
Total	43 (100%)

and motor dysfunction occurred before adipsia. The following case concerns a doctor who kept a detailed record of his daily life from childhood.

Typical case

A 75-year old man. He had never felt the desire to drink water since adolescence. In his junior high school days, he used to give all of his water to his friends when on excursions or during athletic training. Constipation started when he was a university student, and he began using laxatives 3 to 5 times per month. After becoming 70 years old, the severity of his constipation increased to the point where his bowel movements were limited to once every 6 days. Parkinson's disease occurred at the age of 73.

Discussion

Parkinson's disease and dietary factors

There have been a wide range of reports on PD and dietary factors, such as those focusing on excessive intake of animal lipids [8–11], insufficient intake of nicotinic acid (niacin) [12–14], and insufficient intake of antioxidants [20]. A study in Seattle by Anderson et al. [11] with 4 groups of subjects consuming different amounts of animal lipids indicated that the risk of PD increased as animal lipid intake increased, with an odds ratio of 3.30 for those in the group consuming the largest amount. The authors of the report proposed that this could be due to the large effect of oxidative stress caused by animal lipid intake. In a cross-sectional study in Rotterdam focusing on the relationship between antioxidant intake and PD [15], the results indicated that it was harder for subjects in a group taking 10 mg of vitamin E per day to develop PD (OR 0.5, 95% confidence interval; 0.2–0.9). Due to problems with the studies, however, the relationship between PD and dietary factors has as yet not been confirmed.

Coffee consumption and the risk of Parkinson's disease

Recently, extremely interesting reports of various prospective studies [1, 2] indicate that intake of coffee or

caffeine is a preventive factor for PD. In the Boston study [2], subjects were divided into 5 groups receiving varying amounts of caffeine. Compared to the group with the lowest intake of caffeine, the group with the largest intake had an OR of 0.42 for PD. It made no difference whether caffeine intake was via coffee or tea. A study in Hawaii [1] showed that compared to a group drinking only 4 ounces (120 ml) of coffee per day, the OR for a group drinking 28 ounces (840 ml) was reduced by roughly 1/5. The same results were obtained with tea and other caffeinated drinks, indicating that the higher the intake of caffeine, the lower the risk of developing PD.

☞ Parkinson's disease and adipsia

The intake of green tea and other caffeinated drinks by patients in our nutritional survey was certainly significantly small. The small water intake, however, was more statistically significant, and taking into consideration the lack of desire to drink water from a young age, it indicates that insufficient water intake is a more important factor. In the report from Hawaii, intake of 4 ounces (120 ml) and 28 ounces (840 ml) of coffee are statistically compared, but although the difference can be seen to be due to different coffee intake, it could also be interpreted as a reflection of different water intake. In this report, however, water intake was not measured. Adipsia is closely related to constipation, and there are cases of a lack of desire to drink water preceding the appearance of motor dysfunction by up to 50 years, which suggests that adipsia is of primary importance in the appearance of PD. The reason why the lack of desire develops from around the time of childhood is unknown.

It is easy to understand that latent dehydration in PD patients would provide an ideal background for the easy development of chronic symptoms during very hot summers.

☞ Parkinson's disease and constipation

Constipation, which is not a rare condition, is something that increases with age. In the case of PD patients, however, the frequency of constipation is high [16], with reports of the results of many studies showing an onset rate of 28% to 61% [17–19], which is significantly higher than the 6% to 33% of controls. There has also been a report of a high onset rate of 80% [20], which agrees with our results.

Many factors play a role in the mechanism of constipation in PD patients, such as reduced contraction of smooth muscle due to gastrointestinal neuron dysfunction, insufficient exercise, antiparkinson agents, diet and water intake.

The primary mechanism for the onset of constipa-

tion in PD is defecation disorder due to the disease itself, which in turn consists of peripheral and central disorders. The most important peripheral mechanisms are the loss of dopaminergic cells in the large intestine [21], and the degeneration of myoenteric plexus and the appearance of Lewy bodies resulting in reduction and loss of large intestine peristalsis [16]. A lack of synergy between the pelvic floor skeletal muscle, which regulates defecation, and the anal sphincter has been indicated as a central mechanism [22]. Other factors that contribute to a worsening of constipation in PD include insufficient exercise, the effects of antiparkinson agents (levodopa, anticholinergics), antidepressants and other drugs, swallowing dysfunction, diet and water intake [1].

☞ Constipation precedes motor symptoms

Our study indicates that constipation appears roughly 20 years before motor symptoms (12.6 ± 16.4 years before in men, 25.5 ± 19.9 years in women). Although this study relies on data from previous studies, constipation is attracting a great deal of attention, and since there are many cases where the time of onset is accurately recorded, it is probable that the data are reliable. In the same way as our results, many reports clearly indicate that constipation precedes motor symptoms in PD. In a cross-sectional study by Ashraf et al. [23], 10 of 12 PD patients developed constipation an average of 16 years prior to the appearance of motor symptoms. Abbot et al. [3] conducted a prospective study for the Honolulu Heart Program. The subjects of the study, which spanned a period of 24 years, were 6,790 American men of Japanese descent aged 51 to 75, 96 of whom developed PD. It was reported that the lower the frequency of bowel movements at the start of the study, the higher the future risk of PD, with the risk for less than 1 bowel movement per day being 2.7 times that for 1 per day, 4.1 times that for 2 per day, and 4.5 times that for 3 per day. This study indicated that constipation appeared a mean 10 years (5 months to 19 years) before motor symptoms. Abbot et al. could not say that constipation is a cause of PD, but did suggest that the presence or absence of constipation could be useful to define individuals with a high risk of developing PD in the future.

Pathological studies conducted by Braak et al. [4, 5] indicate that Lewy neurites and Lewy bodies, both PD hallmarks, first appear in the dorsal nucleus of vagus. Following pathological changes, they then move up to the brain stem and appear in the raphe nucleus, nucleus giganteocellularis reticularis and substantia nigra, eventually leading to disturbance of the cerebral cortex. It has been reported that the dorsal nucleus of vagus, which regulates gastrointestinal functions, is damaged first, adding support to the idea that constipation precedes motor dysfunction. Braak et al. proposed the hy-

pothesis that the reason why the dorsal nucleus of vagus is damaged first is because an as yet unidentified toxin passes through the mucosal barrier of the intestine, and in a retrograde manner is transported up by VIP neurons as far as the vagus nerve [6]. Further research is required to ascertain whether constipation is simply a pathological phenomenon of PD, or whether it has a specific meaning regarding the cause of PD.

Limitation of the study

Since our study is a cross-sectional study, there are concerns about recall bias. For example, nutritional surveys are influenced if subjects drink more water, consume large quantities of vegetable fiber or make other changes to their eating and drinking habits to alleviate constipa-

tion, resulting in reverse cause. There are also cases of constipation appearing after subjects were administered antiparkinson agents, but it is difficult to confirm whether this is due to an adverse drug reaction or the course of the disease itself. Nevertheless, there are numerous patients who have suffered from constipation for many years, and since in most cases the time of onset is precisely recorded, our results can be considered reliable. Although there are few ordinary patients who can be subjective about their water intake, many spouses and other family members were aware of the patient's low water intake long before motor symptoms appeared. Strictly speaking, however, there is a need for prospective studies to clarify the cause and effect relationship.

From the viewpoint of life style factors, this study offers valuable suggestions for studies of the pathology and cause of sporadic nerve degeneration diseases.

References

- Ross GW, Abbott RD, Petrovitch H, Morens DM, Grandinetti A, Tung KH, Tanner CM, Masaki KH, Blanchette PL, Curb JD, Popper JS, White LR (2000) Association of coffee and caffeine intake with the risk of Parkinson Disease. *JAMA* 283:2674-2679
- Ascherio A, Zhang SM, Hernan MA, Kawachi I, Colditz GA, Speizer FE, Willett WC (2001) Prospective study of caffeine consumption and risk of Parkinson's Disease in men and women. *Ann Neurol* 50:56-63
- Abbott RD, Petrovitch H, White LR, Masaki KH, Tanner CM, Curb JD, Grandinetti A, Blanchette PL, Popper JS, Ross GW (2001) Frequency of bowel movements and the future risk of Parkinson's disease. *Neurology* 57:456-462
- Tredici KD, Rüb U, de Vos RAI, Bohl JRE, Braak H (2002) Where does Parkinson Disease pathology begin in the brain? *J Neuropathol Exp Neurol* 61:413-426
- Braak H, Del Tredici K, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E (2003) Staging of brain pathology related to sporadic Parkinson's disease. *Neurobiol Aging* 24:197-211
- Braak H, Rüb U, Gai WP, Del Tredici K (2003) Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. *J Neural Transm* 110(5):517-536
- Sasaki S, Yanagibori R, Amano K (1998) Validity of a Self-Administered Diet History Questionnaire for assessment of sodium and potassium-comparison with single 24-hour urinary excretion. *Jap Circ J* 62:431-435
- Logroscino G, Marder K, Cote L, Tang MX, Shea S, Mayeux R (1996) Dietary lipids and antioxidants in Parkinson's Disease: A population-based, case-control study. *Ann Neurol* 39:89-94
- Logroscino G, Marder K, Graziano J, Freyer G, Slavkovich V, Lojacocono N, Cote L, Mayeux R (1998) Dietary iron, animal fats, and risk of Parkinson's disease. *Mov Disord* 13:13-16
- Johnson CC, Gorell JM, Rybicki BA, Sanders K, Peterson EL (1999) Adult nutrient intake as a risk factor for Parkinson's disease. *Int J Epidemiol* 28:1102-1109
- Anderson C, Checkoway H, Franklin GM, Beresford S, Smith-Weller T, Swanson PD (1999) Dietary factors in Parkinson's Disease: The role of food groups and specific foods. *Mov Disord* 14:21-27
- Hellenbrand W, Seidler A, Boeing H, Robra BP, Vierегge P, Nischan P, Joerg J, Oertel WH, Schneider E, Ulm G (1996) Diet and Parkinson's disease I: A possible role for the past intake of specific foods and food group. *Neurology* 47:636-643
- Hellenbrand, Boeing H, Robra B-P, Seidler A, Vierегge P, Nischan P, Joerg J, Oertel WH, Schneider E, Ulm G (1996) Diet and Parkinson's disease II: A possible role for the past intake of specific nutrients. *Neurology* 47: 644-650
- Fall P-A, Fredrikson M, Axelson O, Granerus AK (1999) Nutritional and occupational factors influencing the risk of Parkinson's disease: A case-control study in southeastern Sweden. *Mov Disord* 14:28-37
- de Rijk MC, Breteler MM, den Breeijen JH, Launer LJ, Grobbee DE, van der Meche FG, Hofman A (1997) Dietary antioxidants and Parkinson disease. The Rotterdam Study. *Arch Neurol* 54(6):762-765
- Edwards LL, Quigley EMM, Pfeiffer RF (1992) Gastrointestinal dysfunction in Parkinson's disease: frequency and pathophysiology. *Neurology* 42: 726-732
- Edwards LL, Pfeiffer RF, Quigley EM, Hofman R, Balluff M (1991) Gastrointestinal symptoms in Parkinson's disease. *Mov Disord* 6:151-156
- Singer C, Weiner WJ, Sanchez-Ramos JR (1992) Autonomic dysfunction in men with Parkinson's disease. *Eur Neurol* 32:134-140
- Korczyn AD (1990) Autonomic nervous system disturbances in Parkinson's disease. *Adv Neurol* 53:463-468
- Jost WH (1997) Gastrointestinal motility problems in patients with Parkinson's disease: effects of antiparkinsonian treatment and guidelines for management. *Drugs Aging* 10:249-258
- Singaram C, Ashraf W, Gaumnitz EA, Torbey C, Sengupta A, Pfeiffer R, Quigley EM (1995) Dopaminergic defect of enteric nervous system in Parkinson's disease patients with chronic constipation. *Lancet* 346: 861-864
- Byrne KG, Pfeiffer R, Quigley EMM (1994) Gastrointestinal dysfunction in Parkinson's disease: a report of clinical experience at a single center. *J Clin Gastroenterol* 19:11-16
- Ashraf W, Pfeiffer RF, Park F, Lof J, and Quigley EM (1997) Constipation in Parkinson's disease: objective assessment and response to psyllium. *Mov Disord* 12:946-951

No genetic association between tumour necrosis factor receptor II 196R polymorphism and Japanese sporadic Alzheimer's disease

Nobuto Shibata^a, Tohru Ohnuma^a, Tadashi Takahashi^a, Yoichiro Matsubara^a, Akira Ueki^b, Masatsugu Nagao^c and Heii Arai^a

Recent studies have reported that acute effects of tumour necrosis factor (TNF), a pro-inflammatory cytokine, are limited by binding to a soluble receptor, TNF receptor II, and the G allele at position 196 in exon 6 of the TNF receptor II gene (TNFR II 196R) has been associated with auto-immune diseases. Since complex interactions among cytokines have been suggested around senile plaques in Alzheimer's disease, TNF might be associated with ageing and the pathophysiology of Alzheimer's disease. We examined the TNFR II 196R polymorphism in 243 Japanese sporadic Alzheimer's disease cases and 106 control cases using a polymerase chain reaction-restriction fragment length polymorphism method. Allelic frequencies with TNFR II 196R T/G polymorphism were 28.3% and 27.4% in the control and Alzheimer's disease groups, respectively. The results showed no genetic association between TNFR II 196R polymorphism and Alzheimer's disease. The TNFR II 196R G allele does not appear to be associated with Alzheimer's disease susceptibility in a Japanese

population. *Psychiatr Genet* 14:53–55 © 2004 Lippincott Williams & Wilkins.

Psychiatric Genetics 2004, 14:53–55

Keywords: TNFR II 196R, polymorphism, Alzheimer's disease

^aDepartment of Psychiatry, Juntendo University School of Medicine, Tokyo, Japan, ^bDepartment of Neurology, Omiya Medical Center, Jichi Medical School, Saitama, Japan and ^cDepartment of Psychiatry, Nagao Hospital, Hiroshima, Japan.

Sponsorship: This study was in part funded by a High Technology Research Center Grant from the Japanese Ministry of Education, Culture, Sports, Science and Technology, and by a research grant from the Japanese Ministry of Health, Labour and Welfare of Japan.

Correspondence and requests for reprints to Nobuto Shibata, MD, Department of Psychiatry, Juntendo Koshigaya Hospital, 560 Fukuroyama, Koshigaya-shi, Saitama 343-0032, Japan.
Tel: +81 489 750321; fax: +81 489 787821;
e-mail: nobuto.shibata@nifty.ne.jp

Received 20 March 2002 Accepted 26 February 2003

Introduction

Recently, several genetic polymorphisms of inflammatory cytokines including interleukin-6 were reported to be associated with Alzheimer's disease (Papassotiropoulos *et al.*, 1999). It has been reported that chronic low-grade inflammation in ageing promotes an atherogenic profile and is related to age-associated disorders including Alzheimer's disease (Viel *et al.*, 2001). Additionally, a local inflammatory process has been studied as Alzheimer's disease-related neurodegeneration (Blacker *et al.*, 1998; Bruunsgaard *et al.*, 2001), because some epidemiological studies have shown that anti-inflammatory drugs delayed onset of or slowed progression of Alzheimer's disease (Breitner, 1989; McGeer *et al.*, 1990; Breitner *et al.*, 1994; Breitner, 1996; Aisen, 1997).

Tumour necrosis factor (TNF) is one of the pro-inflammatory cytokines and might be involved in inflammatory changes surrounding senile plaques (Collins *et al.*, 2000). It has been confirmed that high levels of TNF together with amyloid β are toxic to neurons in old rats (Viel *et al.*, 2001). It should be noted that one of the TNF polymorphisms, TNFa2, which had been functionally associated with a high TNF production, was recently

reported to genetically associate with Alzheimer's disease (Collins *et al.*, 2000). Therefore, since TNF acts via binding to TNF receptors I and II (TNFR I and TNFR II) (Al-Ansari *et al.*, 2000; Barton *et al.*, 2001), it is of interest to identify whether the TNFR II polymorphism is a risk factor for sporadic Alzheimer's disease.

The gene of TNFR II is mapped on chromosome 1p36. The TNFR II T/G polymorphism at position 196 in exon 6 (TNFR II 196R), which results in an amino acid substitution (methionine to arginine), was reported to be associated with familial rheumatoid arthritis (Barton *et al.*, 2001). In the present study, therefore, we investigated the polymorphism in Japanese sporadic Alzheimer's disease.

Materials and methods

All genomic DNA (gDNA) samples of sporadic Japanese Alzheimer's disease cases ($n = 243$, male: female = 106:137) were obtained from inpatients/outpatients of the hospitals where the authors worked. The mean \pm standard deviation age of the Alzheimer's disease group (69.4 ± 9.9 years, range 38–90 years) was not significantly different from that of the control group

Table 1 Genotype and allelic distribution of the tumour necrosis factor receptor II 196R (TNFR II 196R) polymorphism

	Genotype			Allele	
	T/T	G/T	G/G	T allele	G allele
Alzheimer's disease	133 (54.7%)	87 (35.8%)	23 (9.5%)	353 (72.6%)	133 (27.4%)
Control	56 (52.8%)	40 (37.7%)	10 (9.4%)	152 (71.7%)	60 (28.3%)

(70.3 ± 9.0 years, range 51–93 years). All Alzheimer's disease cases were diagnosed according to the National Institute for Neurological Disease and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria. None had a familial history of Alzheimer's disease. The control cases ($n = 106$, male:female = 54:52) were obtained from healthy volunteers with no history of dementia or other neuropsychiatric diseases. The purpose and significance of this study were explained in detail to each patient and his/her family, and all subjects provided their informed consent. Study protocol was approved by the Ethics committee of Juntendo University School of Medicine.

All gDNA were extracted from white blood cells using a standard method with the Nucleon II kit (Scotlab, UK). The TNFR II 196R genotype was studied by the polymerase chain reaction-restriction fragment length polymorphism analysis method as previously reported (Al-Ansari *et al.*, 2000). The genotypes and allelic distribution between the Alzheimer's disease and control groups were compared using chi-square tests.

Results

The distribution of the TNFR II 196R polymorphism is presented in Table 1. No significant difference was observed in the TNFR II 196R genotype frequencies between the Alzheimer's disease and control groups ($\chi^2 = 0.13$, degrees of freedom = 2, $P = 0.94$). The frequency of the TNFR II 196R G allele was 27.7% in total subjects. There was no significant difference in the frequency of the TNFR II 196R G allele between the Alzheimer's disease group and the control group ($\chi^2 = 0.06$, degrees of freedom = 1, $P = 0.80$). The genotype distribution of the TNFR II 196R was expected under Hardy-Weinberg equilibrium in the Alzheimer's disease and control groups.

Discussion

The present study clearly shows that the allelic and genotype frequencies of the TNFR II gene in Japanese healthy controls are similar to those in a Caucasian population (Al-Ansari *et al.*, 2000; Barton *et al.*, 2001). The results suggest that the inter-ethnic differences in this polymorphism might be few, if any. It was also disclosed that Japanese sporadic Alzheimer's disease cases are

unlikely to be genetically associated with the TNFR II 196R G allele.

There have been several studies that have focused on the association between TNF and the pathophysiology of Alzheimer's disease. It is of interest that positive studies on the association between TNF and Alzheimer's disease (Collins *et al.*, 2000; Viel *et al.*, 2001) have been reported, but no difference of serum TNF between Alzheimer's disease and control groups has been reported (Solerte *et al.*, 2000). Another study has indicated that increased intrathecal production of TNF in AD is preferentially controlled by environmental factors (Tarkowski *et al.*, 2000). Although there might be a complex interaction between TNF and the TNFR affecting the inflammatory process of Alzheimer's disease, our results failed to demonstrate a genetic association between the receptor-site polymorphism and Japanese sporadic Alzheimer's disease. It is still interesting to study the interaction among the genotypes and the several phenotypes (serum, cerebrospinal fluid and brain tissue) of the TNF gene.

Inflammation should modulate the risk for Alzheimer's disease with the abnormality of cytokines (Singh, 1994; Rogers *et al.*, 1996; Singh and Guthikonda, 1997). Further genetic studies of cytokines will be needed to clarify the pathophysiology of Alzheimer's disease.

Acknowledgements

The authors are grateful for the technical assistance of Ms K. Yamamoto and Ms S. Itakura.

References

- Aisen PS (1997). Inflammation and Alzheimer's disease: mechanisms and therapeutic strategies. *Gerontology* 43:143–149.
- Al-Ansari AS, Ollier WER, Villarreal J, Ordi J, Teh L-S, Hajeer AH (2000). Tumor necrosis factor receptor II (TNFR II) exon 6 polymorphism in systemic lupus erythematosus. *Tissue Antigens* 55:97–99.
- Barton A, John S, Ollier WER, Silman A, Worthington J (2001). Association between rheumatoid arthritis and polymorphism of tumor necrosis factor receptor II, but not tumor necrosis factor receptor I, in Caucasians. *Arthritis Rheum* 44:61–65.
- Blacker D, Wilcox MA, Laird NM, Rodes L, Horvath SM, Go Rodney CP, *et al.* (1998). Alpha-2 macroglobulin is genetically associated with Alzheimer disease. *Nat Genet* 19:357–360.
- Breitner JCS (1996). Inflammatory processes and antiinflammatory drugs in Alzheimer's disease: a current appraisal. *Neurobiol Aging* 17:789–794.
- Breitner JCS, Gau BA, Welsh KA, Plassman BL, McDonald WM, Helmas MJ, Anthony JC (1994). Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study. *Neurology* 44:227–232.

- Brunnsgaard H, Pedersen M, Pedersen BK (2001). Aging and proinflammatory cytokines. *Curr Opin Hematol* **3**:131-136.
- Collins JS, Perry RT, Watson B Jr, Harrell LE, Acton RT, Blacker D, *et al.* (2000). Association of a haplotype for tumor necrosis factor in siblings with late-onset Alzheimer disease: the NIMH Alzheimer Disease Genetics Initiative. *Am J Med Genet* **96**:823-830.
- McGeer PL, McGeer E, Rogers J, Sibley J (1990). Antiinflammatory drugs and Alzheimer's disease (Letter). *Lancet* **335**:1037.
- Papassotiropoulos A, Bagli M, Jessen F, Thomas AB, Maier W, Rao ML, Heun R (1999). A genetic variation of the inflammatory cytokine interleukin-6 delays the initial onset and reduces the risk for sporadic Alzheimer's disease. *Ann Neurol* **45**:666-668.
- Rogers J, Webster S, Lue L-F, Brachova L, Harold C, Civin W, Emmerling M, *et al.* (1996). Inflammation and Alzheimer's disease pathogenesis. *Neurobiol Aging* **17**:681-686.
- Singh VK (1994). Studies of neuroimmune markers in Alzheimer's disease. *Mol Neurobiol* **9**:73-81.
- Singh VK, Guthikonda P (1997). Circulating cytokines in Alzheimer's disease. *J Psychiatry Res* **31**:657-660.
- Solerte SB, Cravello L, Ferrari E, Fioravanti M (2000). Overproduction of IFN-gamma and TNF-alpha from natural killer (NK) cells is associated with abnormal NK reactivity and cognitive dearrangement in Alzheimer's disease. *Ann NY Acad Sci* **917**:331-340.
- Tarkowski E, Liljeroth AM, Nilsson A, Ricksten A, Davidsson P, Minthon L, Blennow K (2000). TNF gene polymorphism and its relation to intracerebral production of TNFalpha and TNFbeta in AD. *Neurology* **54**:2077-2081.
- Viel JJ, McManus DQ, Smith SS, Brewer GJ (2001). Age- and concentration-dependent neuroprotection and toxicity by TNF in cortical neurons from beta-amyloid. *J Neurosci Res* **64**:454-465.



International Psychogeriatric Association

Asia Pacific Regional Meeting

**Mental Health of the Elderly
in Rapidly Aging Societies**

**Seoul, Korea
8-11 September 2004
The Shilla Seoul**



In cooperation with
Korean Association for Geriatric Psychiatry



Sponsored by
Ministry of Health and Welfare, Korea

Methods: All subjects and their accompanying caregivers, who came to our geriatric psychiatric clinic, were assessed using the GDS and SPMSQ (Short Portable Mental Status Questionnaire). Caregivers completed the GDS adapted for evaluation of patients, i.e., one in which the questions and answers are in the third person. Somatic complaints, number of physical illnesses, and activities of daily living (PADL and IADL) were assessed in both the patient and caregiver group following procedures performed as GDS administration. In patients with GDS score \geq (self-assessment) and SPMSQ corresponding to normal function (both patient and caregiver), interviews were applied to establish diagnosis according to DSM IV, and severity of depressive symptoms was assessed using the Hamilton Depression Rating Scale (HDRS). X² test was used to analyze categorical variables, and one-way ANOVA was used for continuous variables. Regression analysis was conducted to assess the contribution of the main variables to the prediction of HDRS and GDS scores. Agreement between item scores was determined by X² test and λ value. $P < 0.05$ (two-tailed) was chosen for statistical significance.

Results: Women who were older and had more physical illnesses and disabilities in ADL were thought to be more depressed on the basis of GDS caregiver ratings. HDRS severity correlated with both patients' and caregivers' GDS ratings, patients' IADL ratings, and caregivers' ratings of the number of somatic complaints. The patients' self-assessment and caregivers' assessment of 19 of the GDS items (item 1- 4, 7-8, 10, 11, 14-18, 22, 25-28, and 30) were significantly correlated, and 9 of these showed the highest degree of agreement (1, 7-8, 10, 15, 17, 22, and 26- 27). The resulting GDS (administered by the caregiver to the patient) alpha values were 0.88 for the 30-item, 0.82 for the 19-item, and 0.79 for the 9-item GDS questionnaire. Among of GDS caregiver-based ratings, 5 items could be the major determinants of the total scores obtained by patient self-assessment (1, 13, 16, and 22-23; $R^2=0.419$, $F=15.588$, $P < 0.0005$).

Conclusion: The results of this study suggest that the caregivers of younger elderly men with fewer physical illnesses and greater independent activity consider them to be less depressed. Use of a brief screening instrument modified from the GDS can improve caregiver case identification and lead to appropriate management of geriatric depression.

P063 Relationships between Depression and Dietary Variety in Elderly People Living in a Community

K. Yamashita, Shimane Nursing College, Japan; *Y. Sakamura*, Hiroshima International University, Japan.

Objective: To investigate and measure the relationship between clinical depression and dietary variety in a population of elderly people (65 years or older) living in a rural town.

Materials and Methods: The study used survey methods to question every resident ($n = 609$, 295 male, mean age 73.0 years old, 314 female, mean age 73.7 years old) 65 years or older living in a rural town in Shimane prefecture. The Zung Self-Rating Depression Scale (SDS) was used to assess the depression. For assessing dietary variety, we used the dietary variety score (DVS), counting the number of 10 food groups consumed daily, indicated on food frequency questionnaires: meat, fish and shellfish, eggs, milk, soybean products, potatoes, green yellow vegetables, fruits, seaweed, fat and oil. The DVS ranged from 0 to 10 with higher scores indicating a broader dietary variety.

Results: The average DVS was 3.2 points for men and 3.5 points for women. The SDS however, was significantly higher for women than for men ($p < 0.0005$). In subjects with a depression (high SDS score) 20.5% had low DVS scores and 11.6% had high DVS scores. In addition to these findings, there were significant differences in the food group distribution (fish and shellfish, eggs, milk, green yellow vegetables and fruits) between the depression group and the normal group.

Conclusion: A higher dietary variety is associated with a reduced risk of depression in community elderly.

P064 Prevalence and Correlates of Depressive Disorders among the Elderly in Korea

S.U. Kim, psychiatry, Eulji University School of Medicine, Republic of Korea; *G.H. Suh*, Hallym University College of Medicine, Republic of Korea; *J.P. Hong*, Ulsan University College of Medicine, Republic of Korea; *T. Suh*, Korea Institute of Health and Social Affairs, Republic of Korea; *B.J. Hahm*, Seoul National University College of Medicine, Republic of Korea; *J.Y. Lee*, Seoul National University College of Medicine, Republic of Korea; *E.J. Joo*, Eulji University School of Medicine, Republic of Korea; *M.J. Cho*, Seoul National University College of Medicine, Republic of Korea.

Objective: There is no community study generate the rate of depressive disorder in the Korean elderly by clinical diagnosis through direct interview by psychiatrists.

Design: A two-phase community survey

Materials and Methods: A multi-stage, cluster sampling method was used for the selection of subjects from one rural and one urban community, respectively. A two-phase community survey, screening and diagnostic interview, was conducted.

Results: 1,760 elderly people aged 65 and over completed the interview. The current prevalence rates for major depressive disorder and other depressive disorder were found to be 6.7% (95% CI: 5.5 - 7.3) and 3.1% (95% CI: 2.3 - 3.5), respectively. Four statistically significant correlates associated with depressive disorder were female gender, low economic status, low family APGAR scores, and CAGE score greater than or equal to 2.

Conclusion: Depressive disorder in the Korean elderly was as common as Western European countries and the prevalence rates were much higher than those reported in a number of earlier East Asian studies except for those performed in Taiwan. The authors suggest that the rapid corruption of traditional Confucian ideology and rapid growth of the elderly population influenced on the relatively high prevalence rates.

P065 Prevalence of Depression in Singapore - Results of the National Mental Health Survey of the Elderly in Singapore

P.C. Chiam, Department of Geriatric Psychiatry, Institute of Mental Health, Singapore; *T.P. Ng*, Department of Psychological Medicine, University of Singapore, Singapore; *P.S. Ong*, Department of Geriatric Psychiatry, Institute of Mental Health, Singapore; *L.L. Tan*, Department of Geriatric Psychiatry, Institute of Mental Health, Singapore; *A. Ang*, Department of Geriatric Psychiatry, Institute of Mental Health, Singapore; *L.Y. Kong*, Department of Medical Social Work, Institute of Mental Health, Singapore; *E.H. Kua*, Department of Psychological Medicine, National University of Singapore, Singapore.

抗痴呆薬の効果と今後の展開

群馬県こころの健康センター 所長 宮永和夫

はじめに

抗痴呆薬は、痴呆の中核症状（記憶、見当識、判断力の障害）を改善するか、進行を遅延する薬物と定義できる。

今までの治療の流れを見ると、脳血流改善薬ないし脳代謝改善薬の一群を抗痴呆薬の第一世代と考えることができるが、厚生労働省による再評価の結果、これらの大部分が中核症状に効果を認めないとして中止になってしまった。そのため、一時期抗痴呆薬の概念は消失したように思われたが、タクリンの登場で再度日の目を見ることになった。現在は、この流れを受けてコリン作動薬やモノアミン作動薬などの神経伝達物質を調整する薬物が主流になっているが、これは第二世代と位置づけることができよう。さらに、現在開発中の薬物は、アルツハイマー型痴呆（AD）の病態に直結するアミロイドβ蛋白（Aβ）の蓄積防止や神経成長因子などを標的とするものであり、第三世代として扱うことができると思われる。

現在の日本では、使用可能でかつ有効な抗痴呆薬はドネベジルに限られるため、最初にこの薬物について述べた後、今後登場する予定の第二世代と第三世代の薬物の話をしたい。

1. 現在使用可能な抗痴呆薬

ドネベジル（アリセプト）

日本の製薬メーカーによって作られた薬剤^{*1}であったが、アメリカ、ヨーロッパの販売が先となり、日本では1999（平成11）年に承認された。

薬理作用は、中枢神経系のアセチルコリンエステラーゼ（AChE）^{*2}の働きを阻害する作用が中心で、末梢性コリン系への作用は軽微であるため、副作用が少ない。また、作用時間（半減期は89時間±36時間）が長いので、1日1回の投与で十分である。

ドネベジルの有効率は2分の1から3分の2といわれるが、投与前には効果の有無

※1 薬剤：承認された薬物を意味する。

※2 AChE：神経シナプス間隙に存在する、アセチルコリン分解酵素

は予測できず、実際の投与後の変化から判断しなければならない。また有効な場合でも、改善した知的機能レベルは再度低下し、個人差は大きい。平均2年程度で投与時の知的機能レベルにまで戻るといわれている。

副作用の頻度は、1,291例中142例で約11%と、プラセボ7%と比較して多くみられるため、投与ができない例もある(副作用がひどい場合は、減量して1日3mgにとどめたり、隔日で1.5~2.5mgを投与したりすることもある)。主な副作用は、消化器症状(食欲低下、悪心、嘔吐、下痢、腹痛)、精神症状(不眠、興奮、攻撃性、せん妄)、自律神経症状(頭痛、めまい、動悸、血圧変動)などで、投与開始から1週間以内に見られる。ただし、いずれの症状もブチルスコポラミンで改善することから、末梢のAChE阻害による薬理作用と考えられる。

2. 抗痴呆薬の今後の展開

1) AChE阻害薬(第二世代)

(1) ガランタミン(レミニール)

薬理作用は、AChE阻害と併せてニコチン性アセチルコリン(nACh)受容体結合能を増加させる作用を持つ。現在、アメリカ、ヨーロッパで承認されているが、日本ではヤンセンが治験を行っており、早ければ2年後に承認される予定である。ドネペジルより有効率が高いといわれている。

(2) リバスチグミン(エクセロン)

薬理作用は、AChE阻害のみである。アメリカ、ヨーロッパで承認されている。日本でもノバルティスが治験中である。

(3) タクリン(コグネックス)

AChE阻害薬として最初に承認され、現在、アメリカ、ヨーロッパで使用されている。肝障害などの副作用が強く、日本では今後とも承認される見通しはない。

(4) 今後承認される可能性のある、 AChE阻害作用を持つ薬物

①ヒュペルジンA

コケ植物(ヒカゲノカズラ)の抽出液。AChE阻害作用がある。現在でも通信販売で入手可能である。

②ルバミン酸誘導体(フェネチルアミン、ヒドロキシアミノインダン)

AChE阻害作用とMAO阻害作用がある。Herzigらが報告したが、現在治験が実施されているかは不明である。

③TAK-147(ザナベジル)

AChE阻害作用を持つ。現在、フェーズⅢにある。

(5) すでに発売されているが、 抗痴呆薬の適応がない薬物

①セビメリン(エポザック)

口腔乾燥改善薬として使用されている。ムスカリン性アセチルコリン受容体(M3)に高い親和性があり、イノシトールリン酸の代謝回転を促進する作用を持つ。